Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2A phase 1 randomized clinical trial

被引：0
|
作者：
Peter G. Kremsner
Philipp Mann
Arne Kroidl
Isabel Leroux-Roels
Christoph Schindler
Julian J. Gabor
Mirjam Schunk
Geert Leroux-Roels
Jacobus J. Bosch
Rolf Fendel
Andrea Kreidenweiss
Thirumalaisamy P. Velavan
Mariola Fotin-Mleczek
Stefan O. Mueller
Gianluca Quintini
Oliver Schönborn‑Kellenberger
Dominik Vahrenhorst
Thomas Verstraeten
Margarida Alves de Mesquita
Lisa Walz
Olaf‑Oliver Wolz
Lidia Oostvogels
机构：
[1] University Hospital Tübingen,Institute of Tropical Medicine
[2] German Centre for Infection Research (DZIF),Division of Infectious Diseases and Tropical Medicine, University Hospital
[3] partner site Tübingen,undefined
[4] Centre de Recherches Medicales de Lambarene,undefined
[5] CureVac AG,undefined
[6] LMU Munich,undefined
[7] German Centre for Infection Research (DZIF),undefined
[8] partner site Munich,undefined
[9] Ghent University Hospital,undefined
[10] Hannover Medical School (MHH),undefined
[11] Vietnamese-German Center for Medical Research (VG-CARE),undefined
[12] CureVac AG,undefined
[13] Cogitars,undefined
[14] P95 Epidemiology and Pharmacovigilance,undefined
来源：
Wiener klinische Wochenschrift | 2021年 / 133卷
关键词：
S protein; Reactogenicity; COVID-19; Dose-response; Neutralizing antibodies;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：931 / 941
页数：10
相关论文
共 50 条
  • [1] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 A phase 1 randomized clinical trial
    Kremsner, Peter G.
    Mann, Philipp
    Kroidl, Arne
    Leroux-Roels, Isabel
    Schindler, Christoph
    Gabor, Julian J.
    Schunk, Mirjam
    Leroux-Roels, Geert
    Bosch, Jacobus J.
    Fendel, Rolf
    Kreidenweiss, Andrea
    Velavan, Thirumalaisamy P.
    Fotin-Mleczek, Mariola
    Mueller, Stefan O.
    Quintini, Gianluca
    Schoenborn-Kellenberger, Oliver
    Vahrenhorst, Dominik
    Verstraeten, Thomas
    de Mesquita, Margarida Alves
    Walz, Lisa
    Wolz, Olaf-Oliver
    Oostvogels, Lidia
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (17-18) : 931 - 941
  • [2] Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
    Essink, Brandon J.
    Shapiro, Craig
    Isidro, Marie Grace Dawn
    Bradley, Paul
    Pragalos, Antoinette
    Bloch, Mark
    Santiaguel, Joel
    Frias, Melchor Victor
    Miyakis, Spiros
    de Mesquita, Margarida Alves
    Berre, Stefano
    Servais, Charlotte
    Waugh, Natasha
    Hoffmann, Claudia
    Baba, Emna
    Schoenborn-Kellenberger, Oliver
    Wolz, Olaf-Oliver
    Koch, Sven D.
    Ganyani, Tapiwa
    Boutet, Philippe
    Mann, Philipp
    Mueller, Stefan O.
    Ramanathan, Roshan
    Gaudinski, Martin Robert
    Vanhoutte, Nicolas
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [3] Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
    Yassini, Patrick
    Hutchens, Mark
    Paila, Yamuna D.
    Schoch, Lorraine
    Aunins, Anne
    Siangphoe, Uma
    Paris, Robert
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [4] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
    Chu, Laurence
    McPhee, Roderick
    Huang, Wenmei
    Bennett, Hamilton
    Pajon, Rolando
    Nestorova, Biliana
    Leav, Brett
    VACCINE, 2021, 39 (20) : 2791 - 2799
  • [5] Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial
    Kaabi, Nawal Al
    Yang, Yun Kai
    Liang, Yu
    Xu, Ke
    Zhang, Xue Feng
    Kang, Yun
    Jin, Yu Qin
    Hou, Jun Wei
    Zhang, Jing
    Yang, Tian
    Hussein, Salah
    ElDein, Mohamed Saif
    Lei, Ze Hua
    Zhang, Hao
    Shao, Shuai
    Liu, Zhao Ming
    Liu, Ning
    Zheng, Xiang
    Su, Ji Guo
    Yang, Sen Sen
    Cong, Xiangfeng
    Tan, Yao
    Lei, Wenwen
    Gao, Xue Jun
    Jiang, Zhiwei
    Wang, Hui
    Li, Meng
    Mekki, Hanadi Mekki
    Zaher, Walid
    Mahmoud, Sally
    Zhang, Xue
    Qu, Chang
    Liu, Dan Ying
    Yang, Mengjie
    Eltantawy, Islam
    Xiao, Peng
    Shen, Fu Jie
    Wu, Jin Juan
    Han, Zi Bo
    Du, Li Fang
    Tang, Fang
    Chen, Shi
    Ma, Zhi Jing
    Zheng, Fan
    Hou, Ya Nan
    Li, Xin Yu
    Li, Xin
    Wang, Zhao Nian
    Yin, Jin Liang
    Mao, Xiao Yan
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [6] Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial
    Nawal Al Kaabi
    Yun Kai Yang
    Yu Liang
    Ke Xu
    Xue Feng Zhang
    Yun Kang
    Yu Qin Jin
    Jun Wei Hou
    Jing Zhang
    Tian Yang
    Salah Hussein
    Mohamed Saif ElDein
    Ze Hua Lei
    Hao Zhang
    Shuai Shao
    Zhao Ming Liu
    Ning Liu
    Xiang Zheng
    Ji Guo Su
    Sen Sen Yang
    Xiangfeng Cong
    Yao Tan
    Wenwen Lei
    Xue Jun Gao
    Zhiwei Jiang
    Hui Wang
    Meng Li
    Hanadi Mekki Mekki
    Walid Zaher
    Sally Mahmoud
    Xue Zhang
    Chang Qu
    Dan Ying Liu
    Jing Zhang
    Mengjie Yang
    Islam Eltantawy
    Peng Xiao
    Fu Jie Shen
    Jin Juan Wu
    Zi Bo Han
    Li Fang Du
    Fang Tang
    Shi Chen
    Zhi Jing Ma
    Fan Zheng
    Ya Nan Hou
    Xin Yu Li
    Xin Li
    Zhao Nian Wang
    Jin Liang Yin
    Signal Transduction and Targeted Therapy, 8
  • [7] Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
    Zeng, Guangting
    LANCET MICROBE, 2022, 3 (08): : E561 - E561
  • [8] Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
    Luke Tzu-Chi Liu
    Cheng-Hsun Chiu
    Nan-Chang Chiu
    Boon-Fatt Tan
    Chien-Yu Lin
    Hao-Yuan Cheng
    Meei-Yun Lin
    Chia-En Lien
    Charles Chen
    Li-Min Huang
    npj Vaccines, 7
  • [9] Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial
    Liu, Luke Tzu-Chi
    Chiu, Cheng-Hsun
    Chiu, Nan-Chang
    Tan, Boon-Fatt
    Lin, Chien-Yu
    Cheng, Hao-Yuan
    Lin, Meei-Yun
    Lien, Chia-En
    Chen, Charles
    Huang, Li-Min
    NPJ VACCINES, 2022, 7 (01)
  • [10] Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
    Ai, Liangxia
    Li, Yafei
    Zhou, Li
    Yao, Wenrong
    Zhang, Hao
    Hu, Zhaoyu
    Han, Jinyu
    Wang, Weijie
    Wu, Junmiao
    Xu, Pan
    Wang, Ruiyue
    Li, Zhangyi
    Li, Zhouwang
    Wei, Chengliang
    Liang, Jianqun
    Chen, Haobo
    Yang, Zhimiao
    Guo, Ming
    Huang, Zhixiang
    Wang, Xin
    Zhang, Zhen
    Xiang, Wenjie
    Sun, Dazheng
    Xu, Lianqiang
    Huang, Meiyan
    Lv, Bin
    Peng, Peiqi
    Zhang, Shangfeng
    Ji, Xuhao
    Luo, Huiyi
    Chen, Nanping
    Chen, Jianping
    Lan, Ke
    Hu, Yong
    CELL DISCOVERY, 2023, 9 (01)
12345